ANI Pharmaceuticals, Inc.

ANIP · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders5.4%

Institutions107.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$883.37M	$614.38M	$486.82M	$316.38M	$216.14M	$208.47M	$206.55M	$201.58M	$176.84M	$128.62M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	$87.16M	$63.15M	$73.02M	$79.03M	$48.78M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$111.09M	$584000	$46.97M	-$35.28M	-$39.79M	-$16.02M	$16.35M	$35.36M	$28.33M	$20.08M
Operating income as a percentage of revenue.	12.6%	0.1%	9.6%	-11.2%	-18.4%	-7.7%	7.9%	17.5%	16.0%	15.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$78.34M	-$18.52M	$18.78M	-$47.90M	-$42.60M	-$22.55M	$6.09M	$15.49M	-$1.08M	$3.93M
Net income divided by the number of shares outstanding — profit attributable to each share.	$3.50	$-1.04	$0.86	$-3.05	$-3.40	$-1.88	$0.51	$1.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$3.32	$-1.04	$0.85	$-3.05	$-3.40	$-1.88	$0.50	$1.00	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$285.58M	$144.86M	$221.12M	$48.23M	$100.30M	$7.86M	$62.33M	$43.01M	$31.14M	$27.36M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.44B	$1.28B	$904.42M	$760.09M	$771.60M	$461.19M	$456.79M	$430.60M	$412.14M	$322.86M
All of the company's interest-bearing borrowings, short and long term combined.	$309.11M	$318.28M	$285.67M	$286.52M	$287.37M	$185.69M	$185.75M	$183.01M	$73.30M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$899.65M	$855.17M	$446.82M	$421.55M	$412.86M	$265.49M	$244.00M	$233.34M	$237.38M	$153.22M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$540.72M	$403.68M	$432.75M	$313.69M	$333.89M	$195.70M	$212.79M	$197.26M	$174.76M	$169.65M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$185.22M	$64.02M	$118.96M	-$31.20M	$3.32M	$15.27M	$45.63M	$67.07M	$39.42M	$27.47M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$13.84M	$16.24M	$8.87M	$8.88M	$2.56M	$6.13M	$6.63M	$5.74M	$10.37M	$4.57M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$171.39M	$47.78M	$110.09M	-$40.08M	$765000	$9.13M	$39.00M	$61.33M	$29.05M	$22.91M

	You	Peer avg
P/E	15.5	149.9
Revenue Growth	+25.9%	+11237.1%
ROE	20.5%	14.8%

ANI Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison